Pharmacometric Reviews Increasingly Influence FDA Regulatory Decisions
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Drug makers should routinely perform exposure-response analyses across Phase II and III studies to find consistencies across trials, FDA said in a recent survey of 31 NDAs submitted between 2005 and 2006.